We hypothesize that patients with CAN will manifest different patterns of gene expression profiling (compared with non-CAN controls), detectable in peripheral blood mononuclear cells (PBMCs) and urine cells. By studying differences that exist in peripheral blood or in the graft and its local environment (urine samples), informative biomarkers may be discovered to improve treatment programs.